에 대한 최신 뉴스 Ouster (NYSE:OUST) 주식

Ouster

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CSCO

OUST

SERV

수요일 미국 주식 선물은 혼조의 움직임을 보이며, 오늘 투자자들의 관심을 끌 가능성이 있는 주식은 다음과 같다: 월스트리트는 블링커 인터내셔널(NYSE:EAT)가 개장 전 매출 11억 6천만 달러, 주당 1.65달러의 분기 이익을 보고할 것으로 예상하고 있다. 브링커 주가는 시간외 거래에서 0.1% 하락한 70.35달러를 기록했다.

수요일 주목해야 할 주식: 블링커 인터내셔널, 시스코 그리고 3종목

After-Hours Center

Movers

CZWI

아우스터(NYSE:CZWI)의 주가는 회사가 화요일에 2분기 재무 결과를 발표한 후 17% 이상 급락했다. 보고서의 세부 내용은 다음과 같다.

아우스터는 2분기 실적 발표 후 시간외 거래에서 17% 이상 급락: 그 이유는?

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

LNTH

MORF

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

Ouster Inc

Ouster, Inc. Warrants to purchase Common Stock

Institutional investment in the cryptocurrency space is poised for a massive influx, with hundreds of billions of dollars expected to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138947/bitcoin-zeroes-in-on-100000-but-this-indicator-signals-one-more-brief-correction">enter the market</a> in the coming years, according to Devin Ryan, managing director at JMP Securities.
What Happened: In an <a href="https://www.cnbc.com/video/2024/11/22/crypto-boom-drives-investment-opportunities-with-coinbase-and-robinhood-leading-the-charge.html">interview</a> with CNBC, Ryan emphasized that the evolving regulatory landscape and the increasing acceptance of Bitcoin exchange-traded funds (ETFs) are key catalysts for this transformative growth.
"We have research out saying $220 billion of assets are coming into Bitcoin ETFs in the next three years," Ryan said. "If there is a strategic reserve, that could be hundreds of billions of dollars of assets into Bitcoin."
Ryan pointed out that trading volumes for companies like Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) have surged since the U.S. presidential election. 
Coinbase volumes, for instance, have tripled, reflecting growing interest in the sector. 
"This activity unlocks a lot of innovation that's been held back," Ryan said, noting the potential for significant growth in payments, remittances, stablecoins, and Web3 applications.
Sarah Kunst, managing director at Cleo Capital, echoed Ryan's optimism, noting that institutional money has been waiting on the sidelines for regulatory clarity. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">MicroStrategy Trading At &#8216;Insane&#8217; 256% Premium To Bitcoin Holdings, Research Shows</a>
Kunst highlighted the new U.S. administration&#8217;s potentially more favorable stance toward mergers and acquisitions (M&amp;A) as a driver for ecosystem growth. 
"I think there are people who have not yet gotten in the game who want to get in the game," she said. "This is really crypto's third act."
Kunst identified key players in the space, including crypto exchanges and infrastructure firms, as potential acquisition targets for larger financial institutions. 
"Names like FalconX, the crypto prime brokerage, and Gemini, the crypto marketplace, are likely to attract attention from big acquirers," she stated.
While Bitcoin CRYPTO: BTC) remains the centerpiece of institutional interest, Kunst sees a broadening investment focus. "Meme coins are dangerous—you can make a lot, but you can lose your shirt," she warned. 
Instead, she pointed to stablecoins and cryptocurrency ETFs as safer options, especially for institutions unable to hold crypto directly.
Ryan reinforced this outlook, emphasizing the importance of capital flows. 
"Follow the flows, and the flows are still coming—we're in the early days," he said. 
Beyond Bitcoin ETFs, Ryan expects tens of billions of dollars to flow into other crypto tokens as regulatory uncertainty diminishes, spurring innovation and further investment in the space.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136031/charles-schwab-prepares-for-spot-cryptocurrency-trading-under-new-leadership">Charles Schwab Prepares For Spot Cryptocurrency Trading Under New Leadership</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

HOOD

Bitcoin ETFs Will See Hundreds Of Billions In Inflows, Analyst Predicts

Shaquille O&#8217;Neal is one of the most famous and successful people around, but when it comes to his fortune, he&#8217;s surprisingly relaxed about it. On a recent Dan Patrick Show, Dan asked the NBA legend if he's a billionaire yet and his response was classic Shaq. He casually replied, &#8220;I don&#8217;t know, I never checked.&#8221;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
Instead of closely monitoring his bank balance like many other wealthy individuals, Shaq measures wealth differently. To him, being rich isn't about hitting a specific dollar amount but about being able to take care of his family – <a href="https://www.benzinga.com/personal-finance/24/10/41186647/nba-star-shaq-wanted-to-get-rich-to-buy-his-mother-anything-she-wanted-that-right-there-is-what-">especially his mom</a>.
When a kid recently asked Shaq how it feels to be rich, he gave a heartfelt answer: &#8220;My definition of rich is being able to buy my mother whatever she wants – my favorite person in the world.&#8221; For Shaq, taking care of his mother, who made countless sacrifices when he was growing up, is the ultimate sign of wealth.
In the interview, Shaq recalled moments he'd never forget – <a href="https://www.benzinga.com/personal-finance/24/10/41337452/nba-legend-shaq-was-raised-by-teen-mom-who-fueled-his-success-cant-outplay-me-because-if-you-are">seeing his mom struggle</a>, even wearing the same pair of pants multiple days a week just to make ends meet. That's why, when he started making money, one of his first goals was to ensure his mom never had to struggle again. She was the first person he thought of when he got his big NBA paycheck.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/SHAQ?ref_src=twsrc%5Etfw">@Shaq</a> shares what his definition of being "rich" is. <a href="https://t.co/5ydPVEhGfB">pic.twitter.com/5ydPVEhGfB</a>
&mdash; Dan Patrick Show (@dpshow) <a href="https://twitter.com/dpshow/status/1857147741824278590?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Shaq's motivation comes from seeing his mom's sacrifices and ensuring she's always comfortable. "As long as my mother doesn't have to feel like she felt when we were young, that's my definition of being rich," he said.
Shaq's big heart doesn't stop with his mom. He shared a recent story about being at Walmart, where he spotted a mom with a tall son and three young daughters. The mom was picking out items for her kids and Shaq approached her, asking how much she planned to spend. After learning she was buying only what she could afford, he gave her $5,000 to get everything she needed for her family. Moments like these show what matters most to Shaq – using his money to make life better for others.
Shaq also wants his kids to learn these values. He wants them to understand that just because he has a lot of money doesn't mean they can rely on it without effort. For this reason, he has made it clear that his children must earn a share of his money by becoming good students, <a href="https://www.benzinga.com/personal-finance/24/11/41869301/shaqs-got-a-500-million-fortune-but-his-kids-arent-getting-a-dime-without-earning-it-you-need-3-degrees-to-touch-daddys-cheese">getting multiple diplomas</a> and demonstrating their ability to work hard on their own.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Shaquille O'Neal Says He Doesn't Know If He's A Billionaire Yet – 'I Never Checked.' Here's What Being Rich Means To Him

Morgan Stanley analyst Stephen Byrd maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Overweight and lowers the price target from $109 to $104.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on American Electric Power, Lowers Price Target to $104

For decades, famed value investor&nbsp;Warren Buffett&nbsp;has insisted&nbsp;that he does not try to <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">&#8220;time the market.&#8221;</a> But, his recent sales could serve as a warning sign for investors amid a period of protracted valuations.
What Happened: Buffett&#8217;s Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) has gradually wound down its largest positions over the last year.
Berkshire <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">slashed its largest position</a> in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) by over two-thirds since 2023. Buffett also sold much of his position in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) since the summer. He also trimmed back nearly all of his position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), an atypically short holding period for the investor who preaches investing for the long term.
The Omaha, Nebraska-based company&#8217;s cash horde now stands at an astounding $325 billion.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42137295/as-mstrs-michael-saylor-says-warren-buffett-is-destroying-berkshire-capital-analyst-suggests-ove">As MSTR&#8217;s Michael Saylor Says Warren Buffett Is &#8216;Destroying&#8217; Berkshire Capital, Analyst Suggests &#8216;Overpriced…Hot Stock Market&#8217; Could Be The Reason Oracle Of Omaha Is Sitting On $325B Cash</a>
Why it Matters: Several market experts have struggled to comprehend Buffett&#8217;s thought process — is he bearish on the market at large? Reallocating his portfolio away from Apple and Bank of America to diversify? Or, as Buffett hinted at in May, anticipating a future change to U.S. tax laws?
An <a href="https://www.bloomberg.com/opinion/articles/2024-11-21/buffett-s-325-billion-cash-hoard-is-an-early-warning-signal?srnd=homepage-americas">article</a> from Bloomberg columnist Nir Kaissar could fuel the first theory. A <a href="https://x.com/cullenroche/status/1859644225991987508">post</a> on X relayed a graph from the article showing Buffett&#8217;s cash pile conspicuously rising ahead of financial crises.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Interesting piece here from <a href="https://twitter.com/markets?ref_src=twsrc%5Etfw">@markets</a> and how Buffett's cash hoard often spikes before equity market slowdowns. &#x1f914;&#x1f914;&#x1f914; <a href="https://t.co/9aFmsMpP2N">pic.twitter.com/9aFmsMpP2N</a>
&mdash; Cullen Roche (@cullenroche) <a href="https://twitter.com/cullenroche/status/1859644225991987508?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">The company&#8217;s cash allocation ticked upwards ahead of two large market crashes in 2000 and 2008.</figcaption></figure>
As companies in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) sustain a period of high valuations, Buffett could simply be heeding his advice, &#8220;to be fearful when&nbsp;others are greedy&nbsp;and to be greedy only when others are fearful,&#8221; allocating his portfolio away from what he deems riskier investments
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a></li>
</ul>
Photo: Shutterstock

Equities

AAPL

ULTA

Warren Buffett Claims To Not 'Time The Market,' But His Cash Horde Tells A Different Story

Jefferies analyst Brent Thill maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and raises the price target from $790 to $800.

INTU

Jefferies Maintains Buy on Intuit, Raises Price Target to $800

Morgan Stanley analyst Stephen Byrd maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and lowers the price target from $88 to $86.

Morgan Stanley Maintains Equal-Weight on Ameren, Lowers Price Target to $86

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

General

HALO

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Craig-Hallum analyst Richard Shannon maintains POET Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) with a Buy and raises the price target from $3.5 to $5.5.

POET

Craig-Hallum Maintains Buy on POET Technologies, Raises Price Target to $5.5

Janney Montgomery Scott analyst Christopher Marinac upgrades National Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKSH#NASDAQ">NKSH</a>) from Neutral to Buy and announces $38 price target.

Upgrades

NKSH

Janney Montgomery Scott Upgrades National Bankshares to Buy, Announces $38 Price Target

Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) with a Buy and raises the price target from $8 to $10.

LFCR

Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10

Craig-Hallum analyst Jeff Van Rhee maintains Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Hold and raises the price target from $3.5 to $6.

CRNC

Craig-Hallum Maintains Hold on Cerence, Raises Price Target to $6

DA Davidson analyst Peter Heckmann initiates coverage on CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy rating and announces Price Target of $36.

Initiation

PMTS

DA Davidson Initiates Coverage On CPI Card with Buy Rating, Announces Price Target of $36

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and raises the price target from $10 to $15.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Raises Price Target to $15

RBC Capital analyst Scott Hanold maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Outperform and raises the price target from $102 to $116.

RBC Capital Maintains Outperform on Expand Energy, Raises Price Target to $116

IPOs

Ming Shing Group Shares Open For Trade At $5.65/Share; IPO Priced At $5.50/Share On 1.5M Shares

Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy and raises the price target from $5 to $6.

WALD

Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $6

Macro Economic Events

Economics

Biden Administration Approves New York Plan To Launch $9 Congestion Fee Starting Jan. 5

RBC Capital analyst Rishi Jaluria reiterates Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and maintains $760 price target.

Reiteration

RBC Capital Reiterates Outperform on Intuit, Maintains $760 Price Target

During the last three months, 4 analysts shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.25, with a high estimate of $100.00 and a low estimate of $76.00. Experiencing a 3.59% decline, the current average is now lower than the previous average price target of $90.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294863_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Keros Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Keros Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Keros Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KROS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Keros Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Keros Therapeutics</h2>
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
<h3>Financial Insights: Keros Therapeutics</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Keros Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4750.0% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Keros Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -13648.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Keros Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Keros Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KROS

Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

ICF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.75, a high estimate of $185.00, and a low estimate of $140.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $169.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294854_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive ICF International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Marc Riddick</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$180.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$174.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ICF International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICF International compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ICF International's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICF International's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICFI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICF International analyst ratings.</a>
<h2>All You Need to Know About ICF International</h2>
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian &amp; Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in single segment, which is providing professional services.
<h3>Key Indicators: ICF International's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, ICF International showcased positive performance, achieving a revenue growth rate of 3.09% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: ICF International's net margin excels beyond industry benchmarks, reaching 6.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ICF International's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): ICF International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.62%, the company may face hurdles in achieving optimal financial performance.
Debt Management: ICF International's debt-to-equity ratio is below the industry average at 0.63, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICFI

Expert Outlook: ICF International Through The Eyes Of 4 Analysts

Ouster, Inc. 2024 Q3 - Results - Earnings Call Presentation

Ouster, Inc. (OUST) Q3 2024 Earnings Call Transcript

Ouster, Inc. ( ($OUST) ) has released its Q3 earnings. Here is a breakdown of the information Ouster, Inc. presented to its investors. Ouster, Inc....

Ouster, Inc. Achieves Record Revenue in Q3 2024

Ouster's Real Growth Amid Struggling Competition

Cantor Fitzgerald upgraded Ouster (OUST) to Overweight from Neutral with a price target of $10, down from $12. Published first on TheFly – the ulti...

Ouster upgraded to Overweight from Neutral at Cantor Fitzgerald

As previously reported, Cantor Fitzgerald upgraded Ouster (OUST) to Overweight from Neutral with a price target of $10, down from $12. Ouster recor...

Ouster upgraded to Overweight at Cantor Fitzgerald following underperformance

Ouster (OUST) is up 17.5%, or $1.40 to $9.39. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Ouster rises 17.5%

Luminar Technologies Q3: Progressing Slowly, But I Am Cautiously Optimistic

LiDAR Quarterly Insights Q3 2024 Summary

Ouster: Tip Of The Iceberg

AEVA

INVZ

LAZR

MVIS

Press Releases

Ouster Announces Date for Fourth Quarter 2023 Earnings Call

Ouster Announces Record Revenue for Fourth Quarter and Full Year 2023

Ouster Announces Date for First Quarter 2024 Earnings Call

Ouster Announces Record Revenue and Margin for First Quarter 2024

Ouster Announces Date for Second Quarter 2024 Earnings Call

Ouster Reports Strong Revenue and Margins for Second Quarter 2024

Ouster's Blue City Achieves NEMA TS2 Certification for Safe Traffic Control

Ouster Gemini Launches Genetec Security Center Integration

Ouster Announces Date for Third Quarter 2024 Earnings Call

Ouster Reports Record Performance for Third Quarter 2024

Advanced Energy Industries, Inc. - Common Stock

Advanced Energy Indus

PowerFleet

Arlo Technologies

Badger Meter

Cognex

Crane NXT

Daktronics

Evolv Technologies Holdings, Inc. - Class A Common Stock

Evolv Technologies

Faro Technologies

Itron

Keysight Techs

nLight

Mirion Technologies, Inc. Class A Common Stock

Mirion Technologies

Novanta

NAPCO Security Technologies, Inc. - Common Stock

NAPCO Security Techs

NOVONIX Limited - American Depository Shares

NOVONIX

OSI Systems

PAR Technology

Red Cat Hldgs

SmartRent

Teledyne Technologies Incorporated Common Stock

Teledyne Technologies

Trimble

Vontier

Vishay Precision Group, Inc. Common Stock

Vishay Precision Group

Zebra Technologies Corporation - Class A Common Stock

Zebra Technologies

Rosenblatt

Cantor Fitzgerald

WestPark Capital

Craig-Hallum

Chardan Capital

수요일 미국 주식 선물은 혼조의 움직임을 보이며, 오늘 투자자들의 관심을 끌 가능성이 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 블링커 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>)가 개장 전 매출 11억 6천만 달러, 주당 1.65달러의 분기 이익을 보고할 것으로 예상하고 있다. 브링커 주가는 시간외 거래에서 0.1% 하락한 70.35달러를 기록했다.</li>
<li>서브 로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)가 예상보다 좋은 2분기 매출실적을 발표했다. 서브 로보틱스의 주가는 시간외 거래에서 16.7% 상승한 12.10달러를 기록했다.</li>
<li>분석가들은 시스코 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>)의 분기별 실적이 주당 85센트의 주당 순이익과 135.4억 달러의 매출을 기록할 것으로 예상하고 있다. 이 회사의 실적은 시장 마감 후 발표될 예정이다. 시스코의 주식은 0.1% 하락한 45.35달러에 거래되었다.</li>
</ul>
저희의 <a href="https://www.benzinga.com/premarket/">프리마켓 리뷰에서</a>
<ul>
<li>아우스터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>)는 예상보다 나쁜 2분기 매출 실적을 보고하고 약한 3분기 매출 가이던스를 발표했다. 아우스터의 주가는 시간외 거래에서 16.4% 하락한 9.10달러를 기록했다.</li>
<li>분석가들은 카디널 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/cah" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CAH">CAH</a>)이 개장 전에 매출 7억 7,039만 달러에 주당 36센트의 분기 이익을 게시할 것으로 예상한다. 카디널 헬스의 주가는 시간외 거래에서 1.1% 상승한 103.75달러를 기록했다.</li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아우스터(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZWI#NYSE">CZWI</a>)의 주가는 회사가 화요일에 2분기 재무 결과를 발표한 후 17% 이상 급락했다. 보고서의 <a href="https://www.benzinga.com/pressreleases/24/08/b40350789/ouster-reports-strong-revenue-and-margins-for-second-quarter-2024">세부 내용</a>은 다음과 같다.
주요 정보: 아우스터는 분기별 주당 손실을 53센트로 보고했는데, 이는 분석가들의 합의 추정치인 61센트를 13.11%나 앞선 것이다. 분기별 매출은 2,699만 달러로 분석가 합의 추정치인 2,703만 달러를 하회했다.
이 회사는 매출을 위해 4,000개가 넘는 센서를 출하했으며 2023년 2분기 26%, 2024년 1분기 36%에 비해 비GAAP 총마진은 40%라고 보고했다. 2분기 매출 성장은 주로 스마트 인프라 및 로봇 분야, 특히 경계 보안, 통행료 징수 및 매핑 애플리케이션 분야 고객들의 대량 주문에 의해 주도되었다.
"2분기 결과는 GAAP 총 마진이 34%로 증가하는 등 탄탄한 실행을 보여준다. 소프트웨어 솔루션으로 확장하려는 아우스터의 전략에 따라 우리는 아우스터 제미니(Ouster Gemini) 및 블루 시티(Blue City)를 통해 소프트웨어 관련 판매 부문에서 최고의 분기 중 하나를 기록했다. 지속적인 운영 결과 개선과 함께 업계에서 가장 탄력적인 대차대조표와 다양한 비즈니스 모델을 구축했다"고 아우스터의 CEO인 앵거스 파칼라(Angus Pacala)가 말했다.
전망: 아우스터는 3분기 매출을 2,700만~2,900만 달러로 예상했는데, 이는 해당 분기에 대한 컨센서스 추정치인 3,039만 달러를 밑도는 수치이다. 이 회사는 장기적인 재무 프레임워크를 제공하고 수익성을 달성할 수 있는 궤도에 있다고 말했다.
OUST 주가 움직임: 아우스터의 주식은 화요일 애프터마켓에서 17.28% 하락한 9.00달러에 거래되었다.
사진: Pixabay의 Firmbee
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Ouster

뉴스

에 대한 최신 뉴스 Ouster (NYSE:OUST) 주식

수요일, 8월 14, 2024

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌